<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Gynecol Oncol Res Pract</journal-id><journal-id journal-id-type="iso-abbrev">Gynecol Oncol Res Pract</journal-id><journal-title-group><journal-title>Gynecologic Oncology Research and Practice</journal-title></journal-title-group><issn pub-type="epub">2053-6844</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28286660</article-id><article-id pub-id-type="pmc">5341434</article-id><article-id pub-id-type="publisher-id">40</article-id><article-id pub-id-type="doi">10.1186/s40661-017-0040-2</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Preference of elderly patients&#x02019; to oral or intravenous chemotherapy in heavily pre-treated recurrent ovarian cancer: final results of a prospective multicenter trial</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-9535-3033</contrib-id><name><surname>Chekerov</surname><given-names>Radoslav</given-names></name><address><phone>++49-30-450 664 399</phone><email>radoslav.chekerov@charite.de</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Harter</surname><given-names>Philipp</given-names></name><address><email>p.harter@kliniken-essen-mitte.de</email></address><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Fuxius</surname><given-names>Stefan</given-names></name><address><email>praxis@onko-heidelberg.de</email></address><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Hanker</surname><given-names>Lars Christian</given-names></name><address><email>lars.hanker@uksh.de</email></address><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Woelber</surname><given-names>Linn</given-names></name><address><email>Linn_Woelber@gmx.de</email></address><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>M&#x000fc;ller</surname><given-names>Lothar</given-names></name><address><email>info@onkologie-ue.de</email></address><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Klare</surname><given-names>Peter</given-names></name><address><email>info@drklare.de</email></address><xref ref-type="aff" rid="Aff7">7</xref></contrib><contrib contrib-type="author"><name><surname>Abenhardt</surname><given-names>Wolfgang</given-names></name><address><email>w.abenhardt@onkologie-elisenhof.de</email></address><xref ref-type="aff" rid="Aff8">8</xref></contrib><contrib contrib-type="author"><name><surname>Nedkova</surname><given-names>Yoana</given-names></name><address><email>yoana_nedkova@yahoo.com</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Yalcinkaya</surname><given-names>Isil</given-names></name><address><email>isil.yalcin@charite.de</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Heinrich</surname><given-names>Georg</given-names></name><address><email>g.heinrich@bngo.de</email></address><xref ref-type="aff" rid="Aff9">9</xref></contrib><contrib contrib-type="author"><name><surname>Sommer</surname><given-names>Harald</given-names></name><address><email>harald.Sommer@med.uni-muenchen.de</email></address><xref ref-type="aff" rid="Aff10">10</xref></contrib><contrib contrib-type="author"><name><surname>Mahner</surname><given-names>Sven</given-names></name><address><email>sven.mahner@med.uni-muenchen.de</email></address><xref ref-type="aff" rid="Aff10">10</xref></contrib><contrib contrib-type="author"><name><surname>Wimberger</surname><given-names>Pauline</given-names></name><address><email>pauline.wimberger@uniklinikum-dresden.de</email></address><xref ref-type="aff" rid="Aff11">11</xref></contrib><contrib contrib-type="author"><name><surname>Koensgen-Mustea</surname><given-names>Dominique</given-names></name><address><email>mustea@uni-greifswald.de</email></address><xref ref-type="aff" rid="Aff12">12</xref></contrib><contrib contrib-type="author"><name><surname>Richter</surname><given-names>Rolf</given-names></name><address><email>rolf.richter@charite.de</email></address><xref ref-type="aff" rid="Aff13">13</xref></contrib><contrib contrib-type="author"><name><surname>Oskay-Oezcelik</surname><given-names>G&#x000fc;lten</given-names></name><address><email>guelten.oskay@gmx.de</email></address><xref ref-type="aff" rid="Aff7">7</xref><xref ref-type="aff" rid="Aff13">13</xref></contrib><contrib contrib-type="author"><name><surname>Sehouli</surname><given-names>Jalid</given-names></name><address><email>jalid.sehouli@charite.de</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff13">13</xref></contrib><contrib contrib-type="author"><collab>On behalf of the Ovarian Cancer Study Group of the North-Eastern German Society of Gynaecological Oncology (NOGGO)</collab></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2218 4662</institution-id><institution-id institution-id-type="GRID">grid.6363.0</institution-id><institution>Department of Gynaecology, European Competence Centre for Ovarian Cancer, </institution><institution>Charit&#x000e9; Universit&#x000e4;tsmedizin, </institution></institution-wrap>Berlin, Germany </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 0006 4176</institution-id><institution-id institution-id-type="GRID">grid.461714.1</institution-id><institution>Department of Gynaecology and Gynaecologic Oncology, </institution><institution>Kliniken Essen Mitte, </institution></institution-wrap>Essen, Germany </aff><aff id="Aff3"><label>3</label>Onkologische Schwerpunktpraxis Heidelberg, Heidelberg, Germany </aff><aff id="Aff4"><label>4</label>Department of Gynaecology and Obstetrics, Gynaecological Cancer Center of the University Schleswig-Holstein, Campus L&#x000fc;beck, L&#x000fc;beck, Germany </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2180 3484</institution-id><institution-id institution-id-type="GRID">grid.13648.38</institution-id><institution>Department of Gynaecology and Gynaecologic Oncology, </institution><institution>University Medical Center Hamburg-Eppendorf, </institution></institution-wrap>Hamburg, Germany </aff><aff id="Aff6"><label>6</label>Onkologische Schwerpunktpraxis Leer, Leer, Germany </aff><aff id="Aff7"><label>7</label>Praxisklinik Krebsheilkunde f&#x000fc;r Frauen, Berlin, Germany </aff><aff id="Aff8"><label>8</label>Onkologische Schwerpunktpraxis im Elisenhof, Munich, Germany </aff><aff id="Aff9"><label>9</label>Gyn&#x000e4;kologisch-onkologische Schwerpunktpraxis, F&#x000fc;rstenwalde, Germany </aff><aff id="Aff10"><label>10</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1936 973X</institution-id><institution-id institution-id-type="GRID">grid.5252.0</institution-id><institution>Department of Gynaecology and Obstetrics and Comprehensive Cancer Center, </institution><institution>University of Munich, </institution></institution-wrap>Munich, Germany </aff><aff id="Aff11"><label>11</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2111 7257</institution-id><institution-id institution-id-type="GRID">grid.4488.0</institution-id><institution>Department of Gynecology and Obstetrics, </institution><institution>Technische Universit&#x000e4;t Dresden, </institution></institution-wrap>Dresden, Germany </aff><aff id="Aff12"><label>12</label><institution-wrap><institution-id institution-id-type="GRID">grid.5603.0</institution-id><institution>Department of Gynaecology and Obstetrics, </institution><institution>University Medicine Greifswald, </institution></institution-wrap>Greifswald, Germany </aff><aff id="Aff13"><label>13</label>North-Eastern German Society for Gynaecologic Oncology, Ovarian Cancer Study Group, Berlin, Germany </aff></contrib-group><pub-date pub-type="epub"><day>7</day><month>3</month><year>2017</year></pub-date><pub-date pub-type="pmc-release"><day>7</day><month>3</month><year>2017</year></pub-date><pub-date pub-type="collection"><year>2017</year></pub-date><volume>4</volume><elocation-id>6</elocation-id><history><date date-type="received"><day>24</day><month>11</month><year>2016</year></date><date date-type="accepted"><day>16</day><month>2</month><year>2017</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s). 2017</copyright-statement><license license-type="OpenAccess"><license-p>
<bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p>Palliative systemic treatment in elderly gynaecological cancer patients remains a major challenge. In recurrent ovarian cancer (ROC), treosulfan an active alkylating drug showed similar cytotoxicity whether as oral (p.o.) or intravenous (i.v.) application. The aim of this innovative trial was to evaluate the preference of elderly patients (&#x02265;65&#x000a0;years) for p.o. or i.v. chemotherapy focusing compliance, outcome, toxicities, and geriatric aspects as secondary endpoints.</p></sec><sec><title>Methods</title><p>Patients with ROC had the free choice between treosulfan i.v. (7000&#x000a0;mg/m<sup>2</sup> d1, q29d) or p.o. (600&#x000a0;mg/m<sup>2</sup> daily d1-28, q57d). Only indecisive participants were randomized.</p></sec><sec><title>Results</title><p>Overall 123 patients with 2<sup>nd</sup> to 5<sup>th</sup> recurrence were registered and 119 received at least one cycle of chemotherapy. 85.7% preferred treosulfan i.v. and 14.3% oral, where only three patients were randomized. Main reasons for i.v. preference associated with individual expectations of lower rate of gastrointestinal disorders, higher activity and tolerability of treatment. Median of applied chemotherapies was three (range 1&#x02013;12 cycles), with most common grade 3/4 toxicities thrombopenia (18.7%), leukopenia (15.7%), ascites (7.6%), bowel obstruction (6.7%), and abdominal pain (4.2%). Median time until progression/overall survival was 5.2/7.8&#x000a0;months (i.v.), and 5.6/10.4&#x000a0;months (p.o.), respectively, without significant differences in efficacy.</p></sec><sec><title>Conclusions</title><p>Elderly patients with recurrent ovarian cancer asked and demonstrated active participation in the decision-making process of their oncological treatment and favoured predominantly the i.v. application. Treosulfan was generally well-tolerated despite comorbidities and heavy pre-treatment. Our study demonstrates that patients&#x02019; preference did not influence prognosis negatively and remains important in gynaecologic oncology decision practice.</p></sec><sec><title>EudraCT Nr.</title><p>2004-000719-25; NCT 00170690</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Recurrent ovarian cancer</kwd><kwd>Elderly</kwd><kwd>Patient preference</kwd><kwd>Treosulfan</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2017</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Background</title><p>Treatment of elderly ovarian cancer patients remain a great challenge in the palliative situation, where innovative therapies conflicts with clinical routine [<xref ref-type="bibr" rid="CR1">1</xref>&#x02013;<xref ref-type="bibr" rid="CR3">3</xref>]. In general some physicians consider critical surgical or systemic treatment [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR5">5</xref>] while many observers reported inadequate treatment quality in elderly compared to younger patients [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR6">6</xref>&#x02013;<xref ref-type="bibr" rid="CR8">8</xref>]. Otherwise age was one of the common exclusion criteria in clinical trials, so their results could not consequently be transferred to senior cancer cohorts. Additional, age-dependent limitations of functional reserves are not well understood, but complex and require elaborate assessment [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR10">10</xref>]. In particular, individual preferences and knowledge of patient reported outcome measures are key aspects of palliative concepts [<xref ref-type="bibr" rid="CR11">11</xref>]. Resent published data have confirmed opposing expectations and individual preferences by cancer patients and their physicians [<xref ref-type="bibr" rid="CR11">11</xref>&#x02013;<xref ref-type="bibr" rid="CR13">13</xref>]. Today data focusing elderly ovarian cancer patients, their preferences and expectations for therapy are still limited, thus to change the primary perspective in a clinical trial is provoking but could generate a helpful insight to gynaecologic oncologists.</p><p>As factors of decision-making in oncology are poorly understood, there is an ongoing intensive discussion about new conceptual and scientific approaches [<xref ref-type="bibr" rid="CR14">14</xref>]. Not only efficacy and toxicity, but also patient&#x02019;s acceptance of and compliance with treatment can significantly influence outcome [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR3">3</xref>]. Inadequate therapy of elderly results quite often due to the erroneous belief that age alone determines lower tolerability to surgery and chemotherapy [<xref ref-type="bibr" rid="CR15">15</xref>]. There is also controversial experience that, even in a palliation, elderly women can possibly tolerate debulking surgery and chemotherapy well, but still prediction of the individual aspects, benefits and risk is still not possible [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR16">16</xref>]. Thus optimising strategies for increasing compliance and satisfaction with care should involve patients into the treatment decision-making process, above all respecting their expectations and preferences [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR18">18</xref>].</p><p>Treosulfan is a bifunctional alkylating prodrug showing activity for the i.v. formulation either as a single agent or in combination with other cytotoxic drugs such a cisplatin [<xref ref-type="bibr" rid="CR19">19</xref>&#x02013;<xref ref-type="bibr" rid="CR21">21</xref>]. Furthermore, oral treosulfan demonstrated a high and constant bioavailability [<xref ref-type="bibr" rid="CR22">22</xref>], which may lead to the same efficacy. Since both formulations show a similar efficacy and moderate toxicity, it seems attractive for evaluating individual therapy preferences. Treosulfan is approved in several European countries for the treatment of ovarian cancer and characterized by proven effectivity and mild toxicity (e.g. little hair loss and non-haematological side-effects), which makes it attractive for geriatric and multimorbid patients [<xref ref-type="bibr" rid="CR23">23</xref>].</p><p>The innovative concept of this trial involved elderly patients with recurrent ovarian cancer to determine active their preference for therapy after detailed patient consultation on treatment aims and risks. Primary study objectives were the individual preference and free patient&#x02019;s choice to chemotherapy with either i.v. or p.o. treosulfan. Additionally, we evaluated the reasons for individual choice and analysed compliance, tolerability, and efficacy of the different application routes. Patients were free to participate on geriatric assessment measures.</p></sec><sec id="Sec2" sec-type="materials|methods"><title>Methods</title><sec id="Sec3"><title>Study design</title><p>This was an open-label, multicentre trial of treosulfan in elderly women with ROC. Patients were enrolled into the study after failure of platinum-containing treatment, irrespective of their treatment-free interval, following an innovative registration design: they were free to choose between oral and i.v. treosulfan treatment. Only indecisive participants were randomized.</p><p>Patients were enrolled at 27 German institutions (18 hospitals, nine outpatient facilities). Women&#x02009;&#x02265;&#x02009;65&#x000a0;years with recurrent ovarian, peritoneal, or fallopian tube cancer were eligible. Key inclusion criteria were as follows (selection): ECOG&#x02009;&#x02264;&#x02009;2, serum creatinine&#x02009;&#x02264;&#x02009;1.25 &#x000d7; upper normal limit (UNL), bilirubin&#x02009;&#x02264;&#x02009;1.25 &#x000d7; UNL (in the presence of liver metastases&#x02009;&#x02264;&#x02009;5 &#x000d7; UNL), and adequate bone marrow function (leucocytes&#x02009;&#x02265;&#x02009;2.0&#x02009;&#x000b7;&#x02009;&#x000d7; 10<sup>9</sup>/l, and platelet count&#x02009;&#x02265;&#x02009;100 &#x000d7; 10<sup>9</sup>/l). Initially, only patients in the second line situation (first recurrence) were allowed to participate, but due to emerging trial results and improvement of national guidelines for the treatment of ovarian cancer, the subsequent change of inclusion criteria to patients with at least two previous therapies (&#x02265;3<sup>rd</sup> line situation) was amended.</p><p>The primary aim was to explore the preference and compliance of elderly participants for the palliative treatment with oral or i.v. medication. Secondary objectives included compliance, toxicity, progression-free and overall survival. Additional quality of life, functional and comorbidity measures and geriatric assessments were performed according to the preference of the participants.</p><p>This trial was planned by the North-Eastern German Society of Gynaecological Oncology (NOGGO) Ovarian Cancer Study Group. The study was performed according to ICH-GCP (International Conference on Harmonization - Good Clinical Practice) guidelines after obtaining central ethical committee&#x02019;s approval and trial registration (EudraCT Nr.: 2004-000719-25; NCT 00170690). Written informed consent was provided by each participant.</p></sec><sec id="Sec4"><title>Treatment plan and toxicity evaluation</title><p>Patients received a standard dose of 7000&#x000a0;mg/m<sup>2</sup> treosulfan i.v. on day 1 of a 28-day cycle or 600&#x000a0;mg/m<sup>2</sup> p.o. on days 1&#x02013;28 of a 56-day cycle for a maximum of 12&#x000a0;months or until disease-progression or development of unacceptable toxicity.</p><p>The screening started within 14&#x000a0;days prior to start of therapy included an evaluation of the medical history, a physical examination, and a tumour evaluation, staged by CA 125 and radiological imaging (chest x-ray, ultrasound, CT or MRI scan). Laboratory analyses comprised haematology (biweekly), serum chemistry, and urine analysis. Evaluation of response was performed every 12&#x000a0;weeks or in case of symptoms or signs of tumour progression.</p><p>Toxicity was classified according to the NCI- CTCAE version 2.0. Safety analyses were performed on all patients who received at least one therapy cycle. In order to account for the limited haematopoietic resources of elderly patients, chemotherapy was applied only if leukocyte was&#x02009;&#x02265;&#x02009;3.5 &#x000d7; 10<sup>9</sup>/l and platelets&#x02009;&#x02265;&#x02009;100&#x000d7; 10<sup>9</sup>/l.</p><p>In cases of dose reduction due to severe haematological toxicity, no re-escalation was allowed. Tumour progression, intolerable toxicity (grade 3/4), and/or a treatment delay&#x02009;&#x0003e;&#x02009;2&#x000a0;weeks led to discontinuation of treatment.</p></sec><sec id="Sec5"><title>Statistical analysis</title><p>The preference for oral or i.v. treosulfan was expected to result in a variable compliance. Description of compliance differences between the two treatment arms by 15% was defined as clinically significant. We used Fleiss statistical measurement to optimize the sample size [<xref ref-type="bibr" rid="CR24">24</xref>]. Setting the test criteria to alpha&#x02009;=&#x02009;5%, beta&#x02009;=&#x02009;20% and a drop-out rate of 5%, 160 patients were initially intended to be recruited for this trial. Due to a slow recruitment we performed a prior evaluation with 123 patients identifying highly representative differences in preference and compliance, which were statistically significant to close early trial recruitment.</p><p>Results are presented as proportions, means, medians, and rates, and their adequate measures of distribution. We used a one-sample test of proportions to address the primary hypothesis. All other endpoints were evaluated in an exploratory fashion, and 95% confidence intervals (CI) were computed where appropriate.</p><p>Evaluation of response was performed by CA 125 monthly and by radiological assessment every 3&#x000a0;months. Response was measured according to UICC-criteria and CA-125 assessment criteria, established by Rustin et al. [<xref ref-type="bibr" rid="CR25">25</xref>]. Progression-free survival and overall survival were defined as the interval between the first day of the study drug application and disease progression or death due to any cause. Both were calculated by the Kaplan-Meier method.</p></sec></sec><sec id="Sec6"><title>Results</title><sec id="Sec7"><title>Patient characteristics</title><p>Out of 123 registered patients, 119 received at least one cycle of chemotherapy and were eligible for the final analysis (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>). Generally, there were no significant differences in the global patient characteristics (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>). The median age at recruitment was 71&#x000a0;years (range of 65&#x02013;87 years). Most women were diagnosed with advanced stage III/IV high-grade carcinomas of serous-papillary histology and were in good condition (ECOG 0&#x02013;1). The majority had received three previous cytotoxic treatments (three in the i.v. and two in the oral preference arm). Most patients were treated in this study due to second or third recurrence (56.3%), but 32% had four or more recurrences in their medical history. Because the protocol allowed to register patients independently of their platinum-free interval, the rate of late recurrences with a treatment-free interval &#x0003e;12&#x000a0;months was between 35 and 52% (oral vs. i.v. group). Distant metastases were rare and typically localized to the liver or lung. The median number of concomitant diseases was 5 (range 1&#x02013;9), mostly of cardiovascular, musculoskeletal or gastrointestinal character (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>).<fig id="Fig1"><label>Fig. 1</label><caption><p>CONSORT diagram of trial profile</p></caption><graphic xlink:href="40661_2017_40_Fig1_HTML" id="MO1"/></fig>
<table-wrap id="Tab1"><label>Table 1</label><caption><p>Patients&#x02019; characteristics and distribution of clinical parameters according to individual preference, <italic>n</italic>&#x02009;=&#x02009;119</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2">Parameter of disease (n, %)</th><th colspan="2">Preference to treatment</th></tr><tr><th>i.v. (<italic>n</italic>&#x02009;=&#x02009;102)</th><th>oral (<italic>n</italic>&#x02009;=&#x02009;17)</th></tr></thead><tbody><tr><td>Median age, in years (range)</td><td>72 (65&#x02013;87)</td><td>70 (65&#x02013;77)</td></tr><tr><td colspan="3">ECOG</td></tr><tr><td>&#x02003;0</td><td>22 (21.6)</td><td>4 (23.5)</td></tr><tr><td>&#x02003;1</td><td>68 (66.7)</td><td>10 (58.8)</td></tr><tr><td>&#x02003;2</td><td>12 (11.7)</td><td>3 (17.7)</td></tr><tr><td colspan="3">FIGO stage at primary diagnosis</td></tr><tr><td>&#x02003;I</td><td>2 (2)</td><td>1 (5.9)</td></tr><tr><td>&#x02003;II</td><td>7 (6.9)</td><td>1 (5.9)</td></tr><tr><td>&#x02003;III</td><td>62 (60.8)</td><td>13 (76.5)</td></tr><tr><td>&#x02003;IV</td><td>25 (24.5)</td><td>2 (11.7)</td></tr><tr><td>&#x02003;not documented</td><td>6 (5.9)</td><td>-</td></tr><tr><td colspan="3">Histology</td></tr><tr><td>&#x02003;Serous papillary</td><td>59 (57.8)</td><td>13 (76.5)</td></tr><tr><td>&#x02003;Mucinous</td><td>12 (11.7)</td><td>3 (17.7)</td></tr><tr><td>&#x02003;Endometrioid</td><td>8 (7.8)</td><td>1 (5.9)</td></tr><tr><td>&#x02003;Others or NOS</td><td>23 (22.6)</td><td>-</td></tr><tr><td colspan="3">Grading at primary diagnosis</td></tr><tr><td>&#x02003;G1</td><td>2 (2)</td><td>-</td></tr><tr><td>&#x02003;G2</td><td>29 (28.4)</td><td>5 (29.4)</td></tr><tr><td>&#x02003;G3</td><td>61 (59.8)</td><td>12 (70.6)</td></tr><tr><td>&#x02003;not documented</td><td>10 (9.8)</td><td>-</td></tr><tr><td colspan="3">Type of treatment in the adjuvant situation or last recurrence</td></tr><tr><td>&#x02003;Surgical tumordebulking</td><td>100 (98)</td><td>17 (100)</td></tr><tr><td>&#x02003;Chemotherapy</td><td>101 (99)</td><td>17 (100)</td></tr><tr><td>&#x02003;Previous hormonal treatment</td><td>8 (7.8)</td><td>2 (11.8)</td></tr><tr><td>&#x02003;Previous Radiotherapy</td><td>6 (5.9)</td><td>1 (5.9)</td></tr><tr><td colspan="3">Relapse-free interval after primary platinum based therapy</td></tr><tr><td>&#x02003;&#x02009;&#x0003c;&#x02009;6&#x000a0;months</td><td>21 (20.6)</td><td>4 (23.5)</td></tr><tr><td>&#x02003;6&#x02013;12 months</td><td>28 (27.5)</td><td>7 (41.2)</td></tr><tr><td>&#x02003;&#x02009;&#x0003e;&#x02009;12&#x000a0;months</td><td>53 (51.9)</td><td>6 (35.3)</td></tr><tr><td colspan="3">Type of previous chemotherapy regimens (<italic>n</italic>&#x02009;=&#x02009;372)</td></tr><tr><td>&#x02003;platinum/taxan based</td><td>182 (56.9)</td><td>22 (44.9)</td></tr><tr><td>&#x02003;anthracyclin</td><td>38 (11.9)</td><td>6 (12.2)</td></tr><tr><td>&#x02003;topotecan</td><td>45 (14)</td><td>9 (18.4)</td></tr><tr><td>&#x02003;taxan</td><td>12 (3.8)</td><td>1 (2.1)</td></tr><tr><td>&#x02003;others</td><td>43 (13.4)</td><td>11 (22.4)</td></tr><tr><td>No. of previous chemotherapies for all median (min. / max.)</td><td colspan="2">3 (1&#x02013;8)</td></tr><tr><td/><td>3 (1&#x02013;8)</td><td>2 (1&#x02013;7)</td></tr><tr><td colspan="3">Recurrent situation at time of registration</td></tr><tr><td>&#x02003;1. Recurrence</td><td>13 (12.7)</td><td>1 (5.9)</td></tr><tr><td>&#x02003;2. Recurrence</td><td>25 (24.5)</td><td>8 (47)</td></tr><tr><td>&#x02003;3. Recurrence</td><td>30 (29.4)</td><td>4 (23.5)</td></tr><tr><td>&#x02003;4. Recurrence</td><td>15 (14.7)</td><td>2 (11.8)</td></tr><tr><td>&#x02003;&#x02009;&#x0003e;&#x02009;4 Recurrencies</td><td>19 (18.6)</td><td>2 (11.8)</td></tr></tbody></table></table-wrap>
<table-wrap id="Tab2"><label>Table 2</label><caption><p>Reasons for treatment preference and concomitant diseases (<italic>n</italic>&#x02009;=&#x02009;119)</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Characteristics</th><th>i.v., <italic>n</italic>&#x02009;=&#x02009;102, (%)</th><th>Oral, <italic>n</italic>&#x02009;=&#x02009;17, (%)</th></tr></thead><tbody><tr><td>Preference to therapy regime</td><td>99 (83.2)</td><td>17 (14.3)</td></tr><tr><td>Randomization (for indecisive patients)</td><td>3 (2.5)</td><td>0</td></tr><tr><td colspan="3">Main reasons for therapy preference</td></tr><tr><td>&#x02003;Wish to avoid gastrointestinal disorders</td><td>20 (19.6)</td><td>0</td></tr><tr><td>&#x02003;Disfavour / poor toleration of oral drugs</td><td>12 (17.8)</td><td>0</td></tr><tr><td>&#x02003;Oblivion / daily oral intake is unsure</td><td>14 (13.7)</td><td>0</td></tr><tr><td>&#x02003;Believe i.v. application is saver over i.v. port</td><td>15 (14.7)</td><td>0</td></tr><tr><td>&#x02003;More effective / higher treatment pressure</td><td>13 (12.3)</td><td>1 (5.9)</td></tr><tr><td>&#x02003;Oral drug application not possible - short bowel/subileus</td><td>4 (3.9)</td><td>0</td></tr><tr><td>&#x02003;Pre-existing chronic diarrhoea / vomiting</td><td>4 (3.9)</td><td>0</td></tr><tr><td>&#x02003;Expect better tolerability</td><td>4 (3.9)</td><td>0</td></tr><tr><td>&#x02003;Wish no hospital treatment / more independence / privacy</td><td>0</td><td>6 (35.3)</td></tr><tr><td>&#x02003;The handling of the therapy is simple</td><td>0</td><td>4 (23.5)</td></tr><tr><td>&#x02003;Continuity of the drug administration / maintenance effect</td><td>0</td><td>2 (11.8)</td></tr><tr><td>&#x02003;Made bad experience with venous puncture</td><td>0</td><td>1 (5.9)</td></tr><tr><td>&#x02003;Reason for preference not documented</td><td>16 (17.6)</td><td>3 (17.7)</td></tr><tr><td colspan="3">Concomitant diseases (multiple answers)</td></tr><tr><td>&#x02003;Cardiovascular</td><td>92 (90.2)</td><td>17 (100)</td></tr><tr><td>&#x02003;Musculoskeletal</td><td>37 (36.3)</td><td>7 (41.2)</td></tr><tr><td>&#x02003;Pulmonary</td><td>28 (27.5)</td><td>2 (11.8)</td></tr><tr><td>&#x02003;Lower gastrointestinal tract</td><td>39 (38.2)</td><td>4 (23.5)</td></tr><tr><td>&#x02003;Upper gastrointestinal tract</td><td>27 (26.5)</td><td>4 (23.5)</td></tr><tr><td>&#x02003;Metabolic and hormonal</td><td>25 (24.5)</td><td>6 (35.3)</td></tr><tr><td>&#x02003;Hepatic</td><td>27 (26.5)</td><td>3 (17.7)</td></tr><tr><td>&#x02003;Renal</td><td>12 (11.8)</td><td>6 (35.3)</td></tr><tr><td>&#x02003;Urinary tract</td><td>21 (20.6)</td><td>2 (11.8)</td></tr><tr><td>&#x02003;Neurological</td><td>27 (26.5)</td><td>7 (41.2)</td></tr><tr><td>&#x02003;Psychiatric</td><td>6 (5.9)</td><td>4 (23.5)</td></tr></tbody></table></table-wrap>
</p></sec><sec id="Sec8"><title>Preference for chemotherapy</title><p>During the registration process patients were asked to realize their preference or to be randomized to treatment. Most them (<italic>n</italic>&#x02009;=&#x02009;116, 97.5%) preferred to choose the application form of chemotherapy, thus only 3 indecisive women were randomized. A total of 85.7% or 102 patients realized their free choice to receive chemotherapy as i.v. application, where three were randomized to this arm. Seventeen patients (14.3%) preferred the oral therapy (no randomization to oral therapy). The main reasons for individual preference to i.v. or p.o. treosulfan are listed in Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>.</p></sec><sec id="Sec9"><title>Toxicity profile</title><p>In both treatment arms, most non-haematological and haematological toxicities were of grade 1 or 2. The most common grade 3/4 haematological side-effects were thrombocytopenia, leukopenia, and neutropenia. Severe non-haematological events were rare. Moreover, a remarkably low rate of alopecia was observed (13.7% with grade 1/2, no grade 3). No therapy-related death was observed (Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>).<table-wrap id="Tab3"><label>Table 3</label><caption><p>Toxicity, dose reduction and reasons for therapy discontinuation (<italic>n</italic>&#x02009;=&#x02009;119)</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Parameter</th><th>i.v., <italic>n</italic>&#x02009;=&#x02009;102 (%)</th><th>Oral, <italic>n</italic>&#x02009;=&#x02009;17 (%)</th></tr></thead><tbody><tr><td>Toxicity (grade 3 or 4)</td><td>742 AE&#x02019;s <sup>a</sup>
</td><td>14 AE&#x02019;s</td></tr><tr><td colspan="3">Haematological (all grade)</td></tr><tr><td>&#x02003;Thrombocytopenia</td><td>38.6</td><td>30</td></tr><tr><td>&#x02003;Leucopenia</td><td>27.3</td><td>50</td></tr><tr><td>&#x02003;Neutropenia</td><td>16.3</td><td>10</td></tr><tr><td>&#x02003;Anemia</td><td>11.6</td><td>10</td></tr><tr><td>&#x02003;Febrile Neutropenia</td><td>7</td><td>-</td></tr><tr><td colspan="3">Non-haematological (all grade)</td></tr><tr><td>&#x02003;Ascites</td><td>9.9</td><td>11</td></tr><tr><td>&#x02003;Subileus (severe constipation)</td><td>8.6</td><td>11</td></tr><tr><td>&#x02003;Constipation</td><td>6.2</td><td>-</td></tr><tr><td>&#x02003;Abdominal pain</td><td>4.9</td><td>11</td></tr><tr><td>&#x02003;Ileus (bowel obstruction)</td><td>4.9</td><td>-</td></tr><tr><td>&#x02003;Vomiting</td><td>4.9</td><td>-</td></tr><tr><td>&#x02003;Nausea</td><td>3.7</td><td>-</td></tr><tr><td>&#x02003;Diarrhoea</td><td>2.5</td><td>11</td></tr><tr><td>&#x02003;Rectal incontinence</td><td>2.5</td><td>-</td></tr><tr><td>&#x02003;Others (&#x0003c; 1%)</td><td>51.8</td><td>56</td></tr><tr><td>Dose reduction (27 of all 421&#x000a0;cycles)</td><td colspan="2">6.4</td></tr><tr><td>&#x02003;(26 of 376 i.v. cycles vs. 1 of 45 oral cycles)</td><td>6.9</td><td>2.2</td></tr><tr><td>Prolongation of treatment interval (&#x0003e; 14d)</td><td>25</td><td>4.4</td></tr><tr><td colspan="3">Reasons for early therapy discontinuation</td></tr><tr><td>&#x02003;Progressive disease</td><td>42</td><td>47.1</td></tr><tr><td>&#x02003;Patients preference</td><td>15.7</td><td>11.8</td></tr><tr><td>&#x02003;Other reasons</td><td>15.7</td><td>11.8</td></tr><tr><td>&#x02003;Haematological toxicity (grade 3/4)</td><td>11.8</td><td>-</td></tr><tr><td>&#x02003;Dead of tumour</td><td>5.9</td><td>11.8</td></tr><tr><td>&#x02003;Non-haematological toxicity (grade 3/4)</td><td>2.9</td><td>11.8</td></tr><tr><td>&#x02003;Concomitant disease</td><td>2.9</td><td>5.9</td></tr><tr><td>&#x02003;Complete remission</td><td>1</td><td>-</td></tr><tr><td colspan="3">Main cause of death</td></tr><tr><td>&#x02003;Tumour related</td><td>80.4</td><td>82.4</td></tr><tr><td>&#x02003;Others</td><td>7.8</td><td>5.9</td></tr></tbody></table><table-wrap-foot><p>
<sup>a</sup>adverse events</p></table-wrap-foot></table-wrap>
</p></sec><sec id="Sec10"><title>Treatment delay and discontinuation</title><p>In total, 421&#x000a0;cycles of treosulfan (median 3, range 1&#x02013;12) were administered. Dose reductions were performed in 27 courses of treosulfan therapy (6.4%, 1 oral and 26 i.v. arm, see Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>), whereas for 96 courses (22.8%), an interval prolongation was necessary. The main reason for dose reduction were haematological AEs and for treatment delay haematological toxicity and organisational reasons/preference.</p><p>Six Patients (35.3%) preferring oral application received three courses of therapy, but only three patients (17.6%) finished all planned 6&#x000a0;cycles (12&#x000a0;months). In the i.v. group, 26 patients (25.4%) received six courses, but only one received the maximum of 12 chemotherapies. Disease progression and patient&#x02019;s choice were main reasons for discontinuing treatment. Subsequently 11.8% of the i.v. participants discontinued therapy due to haematological toxicities, whereas non-haematological events were twice as high in the oral group (Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>).</p></sec><sec id="Sec11"><title>Response, survival, and follow-up</title><p>Seventy-four patients (65 i.v./ 9 p.o.) were considered assessable for radiological response. One patient showed complete response (1/0), 13 (11/2) partial remission (PR), 15 (14/1) stable disease (SD), 45 (39/6) progressive disease (PD), and 45 were not assessable for response (lost of follow-up). During the study follow-up period, 105 patients (88.2%) died, mostly documented to disease progress.</p><p>Median follow-up was 11.4&#x000a0;months. Median progression-free survival in this study was 3.7&#x000a0;months (i.v. 3.5&#x000a0;months/p.o. 4.2&#x000a0;months). Median overall survival was 8.0&#x000a0;months, with 7.8&#x000a0;months (i.v.) and 10.4&#x000a0;months (p.o.), respectively (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>). There was no statistically significant difference between the two arms regarding survival.<fig id="Fig2"><label>Fig. 2</label><caption><p>Distribution of severe geriatric assessment inside patients with i.v. and oral preference. ADL&#x02009;=&#x02009;activities of daily living; iADL&#x02009;=&#x02009;instrumental activities of daily living</p></caption><graphic xlink:href="40661_2017_40_Fig2_HTML" id="MO2"/></fig>
</p></sec><sec id="Sec12"><title>Geriatric aspects</title><p>The highest participation in the geriatric assessment with ADL and iADL questionnaires was achieved at the start of therapy (70%), but declined during the study period to less than 10%. Interestingly the proportion of patients which declared to need support or help in their activities of daily living (ADL) was significantly higher within the individuals with preference for oral treatment, but this effect was not demonstrated for the iADL-score. Geriatric measurements did not demonstrate specific differences in the patient preference profiles (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>).</p></sec></sec><sec id="Sec13"><title>Discussion</title><p>The key objectives in the treatment of recurrent ovarian cancer (ROC) are preventing disease-related symptoms, prolonging progression-free survival, and maintaining quality of life [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR26">26</xref>]. However, as more patients achieve long-term survival, palliative care has evolved to include all aspects of cancer survivorship, which increase the need of new and thoroughly considered approaches focusing individual expectations, preference and acceptance of treatment [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR28">28</xref>]. Demographic switch increase the expectations on clinicians and health care providers, since multimodal management and identification of subgroups with specific tumour characteristics is gaining key importance [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR29">29</xref>]. In this prospective study, we evaluated the new strategy giving elderly patients the opportunity to choose free the application route of their chemotherapy and analysed prospectively their preferences. The great majority of 97% realized their preference, demonstrating clearly high motivation to participate to the decision making process. Unexpectedly most patients preferred the i.v. application of the drug, associating oral intake over long period with expected higher gastrointestinal risks for reflux, hyperacidemia, nausea, change of taste, loss of appetite or diarrhoea.</p><p>The monthly i.v. infusion seemed for many to be more comfortable, since regular hospital and physician contacts does not negatively influence patient&#x02019;s autonomy and compliance, as described by others [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR18">18</xref>]. These findings are remarkable, as physicians tend often to inconsequent management of geriatric patients [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR26">26</xref>]. Multiple analyses demonstrated in the past, that elderly were treated suboptimal, commonly under-represented in clinical trials, which resulted in their unfavourable outcome [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR7">7</xref>]. Although data do not support the suggestion that age &#x02013; independently of any other factors &#x02013; is a negative prognostic factor, we need new clinical instruments to evaluate additionally aspects of acceptance, preference and satisfaction with care, as well as social and psychological scopes of treatment [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR5">5</xref>]. Our trial offers here unique aspects and insights to traditional management and can help for more individualisation of palliative ovarian cancer care.</p><p>Patient&#x02019;s preference is known to be complex, to base on individual experiences and reflecting on relevant life events and be difficult to assess [<xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR31">31</xref>]. Acceptance of and compliance with oncological therapy plays a key role for improving efficacy and prolonging survival. Age is the strongest demographic factor affecting patients&#x02019; preferences: younger and better-educated patients, and women in general, were reported to prefer more active role in decision-making [<xref ref-type="bibr" rid="CR31">31</xref>]. Degner et al. identified a large variation in preferred and attained levels of involvement in the treatment decisions for breast cancer patients [<xref ref-type="bibr" rid="CR32">32</xref>]. Our analysis identified that, even after extensive pre-treatment (median of 3 previous therapies) and in highly palliative situation elderly ovarian cancer patients prefer to realize their individual preference and accept the corresponding treatment. Therapy discontinuation remained low, mostly due to tumour progression or toxicity. The i.v. regimen seems to demonstrate a partly favourable toxicity compared to oral treosulfan. Interestingly, this corresponds with the patients&#x02019; expectation of a milder effect on the gastrointestinal tract, which, in turn, was declared to guarantee more safety. On the other hand, patients expected a better control over their treatment since the application takes place in a hospital/outpatient department and associated the corresponding influence with expected positively affection on their outcome. This reflects report of close relationship of oncological patients to their treating physicians and palliative care teams as one of their most important representatives during the treatment [<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR28">28</xref>]. Otherwise the possibility of realizing one&#x02019;s own preference evidently has the strongest psychological impact [<xref ref-type="bibr" rid="CR33">33</xref>].</p><p>Despite all limitations of the small patient cohort and the non-mandatory evaluation of geriatric measures, this trial report interesting insight into a very complex palliative cohort of geriatric patients. Although the observed disease stabilisation was mostly brief, only a small number of participants interrupted their study participation at their own request, keeping their compliance and acceptance high. Despite methodical limitations due to the imbalance of patient distribution, our results are comparable with data by Pfeiffer et al, who reported preference for i.v. chemotherapy within colon cancer outpatients, probably due to expected lower toxicity [<xref ref-type="bibr" rid="CR18">18</xref>].. In contrast, other groups reported preference for oral chemotherapy, within younger breast cancer patients associated with their better functional and physiological status, less comorbidities, and the wish for more individuality in their daily activities [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR13">13</xref>].. A certain bias in the trial design consisted, perhaps, in the fact that, in most cases, in these trials an established i.v. drug was compared to an &#x0201c;innovative&#x0201d; oral formulation, which seemed more attractive [<xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR32">32</xref>, <xref ref-type="bibr" rid="CR34">34</xref>].</p><p>The frequency of concomitant diseases registered in our cohort was high, mostly of moderate severity, and, typically, resulted in more co-medication. It is well-known that multimorbidity may influence patient decisions, favouring tolerability while trying to balance risks and potential benefits [<xref ref-type="bibr" rid="CR6">6</xref>]. Recently published data has not reported significant impact on early treatment discontinuation of chemotherapy in cohort of 1213 patients with relapsed ovarian cancer [<xref ref-type="bibr" rid="CR35">35</xref>]. Although only some physical and emotional domains of quality of life were described most salient, there is no prospective evaluation in ovarian cancer patients and distinct domains are more than heterogeneous [<xref ref-type="bibr" rid="CR36">36</xref>, <xref ref-type="bibr" rid="CR37">37</xref>]. Exemplarily patients after extensive tumour debulking with gross bowel resection, who are not able to resorb oral drugs due to consequently insufficient bowel metabolism, needs quite different treatment strategy as an elderly and frail patient with accumulated gastrointestinal toxicity [<xref ref-type="bibr" rid="CR35">35</xref>, <xref ref-type="bibr" rid="CR38">38</xref>]. Thus, knowledge of late effects of cancer survivals and their individual preferences could help to modify possible ineffective treatment and increase satisfaction with care, but have to be studied systematic in a prospective approach [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR38">38</xref>].</p><p>Summarising elderly ovarian cancer patients demonstrated a high motivation to realize their treatment preference, despite their comorbidity, co-medication and previous chemotherapy experience. The preference for i.v. chemotherapy in this palliative cohort could be described with subjective expectations and individual explanations to toxicity, safety and treatment potency which are difficult to be quantified objective. As expected there were no severe toxicities or differences in efficacy observed [<xref ref-type="bibr" rid="CR39">39</xref>, <xref ref-type="bibr" rid="CR40">40</xref>]. Thus the concept of a patient&#x02019;s free choice following preference for the drug application form could be an attractive option in the treatment of ROC, especially in elderly and comorbid patients with heavily pre-treated recurrence.</p></sec><sec id="Sec14"><title>Conclusions</title><p>Elderly patients with recurrent ovarian cancer have clear preferences and are motivated to participate to the treatment decision process. In the palliative situation they preferred the i.v. application of treosulfan, based on individual experience with toxicity, comorbidity and co-medication, which reflects their specific geriatric situation.</p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>ADL</term><def><p>Activities of daily living</p></def></def-item><def-item><term>AE</term><def><p>Adverse event/s</p></def></def-item><def-item><term>ECOG</term><def><p>Eastern Cooperative Oncology Group</p></def></def-item><def-item><term>iADL</term><def><p>Instrumental activities of daily living</p></def></def-item><def-item><term>ROC</term><def><p>Recurrent ovarian cancer</p></def></def-item></def-list></glossary><ack><title>Acknowledgements</title><p>We would like to thank the Ovarian Cancer Study Group of the North-Eastern Society for Gynaecological Oncology (NOGGO) for concept, coordination, data management and follow-up acquisition.</p><p>The authors acknowledge Alcedis GmbH, Giessen, Germany for independent data monitoring and processing.</p><p>This study was presented in part at the 14th Biennial Meeting of the International Gynaecologic Cancer Society, Vancouver, Canada, October 13&#x02013;16, 2012</p><sec id="FPar1"><title>Funding</title><p>This study was sponsored by</p><p>Medac Gesellschaft fuer klinische Spezialpraeparate mbH, Headquarters: Hamburg</p><p>Managing directors: Heiner Will, Dr. Rainer Dickhardt, Joerg Hans, Jens Denker, Nikolaus Graf Stolberg, Dr. Ulrich Kosciessa; Register court: Hamburg HRB 14 332</p><p>The design of the study, patient collection and registration, analysis and interpretation of data and the writing of this manuscript was organized and coordinated only by the authors and the Ovarian Cancer Study Group of the North-Eastern Society for Gynaecological Oncology (NOGGO).</p></sec><sec id="FPar2"><title>Availability of data and materials</title><p>Please contact authors for data requests.</p></sec><sec id="FPar3"><title>Authors&#x02019; contributions</title><p>RC, RR, GOO and JS participated in the design of the study and performed the statistical analysis. RC, PK, GH, HS, SM, DKM and JS conceived of the study, and participated in its design and coordination and helped to draft the manuscript. PH, SF, LRH, LW, LM, WA, YN, IY, PW, RR, GOO participated in the study and helped to draft the manuscript. All authors read and approved the final manuscript.</p></sec><sec id="FPar4"><title>Competing interests</title><p>The authors declare that they have no competing interests.</p></sec><sec id="FPar5"><title>Consent for publication</title><p>&#x0201c;Not applicable&#x0201d;.</p></sec><sec id="FPar6"><title>Ethics approval and consent to participate</title><p>All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.</p><p>The ethical approval was obtained by the ethical committee of the Charit&#x000e9; University Hospital of Berlin, Statementnumber: 145/2004, from 25.08.2004</p><p>Ethik-Kommission der Medizinischen Fakult&#x000e4;t Charit&#x000e9; am Campus Virchow-Klinikum, Mr. Ass. Jur. C. von Dewitz; Augustenburger Platz 1, 13353 Berlin</p><p>Statement number (Vorgangsnummer): 145/2004, from 25.08.2004</p></sec><sec id="FPar7"><title>Informed consent to participate</title><p>Informed consent was obtained from all individual participants included in the study.</p></sec></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bonanni</surname><given-names>B</given-names></name><name><surname>Lazzeroni</surname><given-names>M</given-names></name></person-group><article-title>Acceptability of chemoprevention trials in high-risk subjects</article-title><source>Ann Oncol</source><year>2013</year><volume>24</volume><issue>Suppl 8</issue><fpage>viii42</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1093/annonc/mdt328</pub-id><pub-id pub-id-type="pmid">24131969</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hall</surname><given-names>M</given-names></name><name><surname>Rustin</surname><given-names>G</given-names></name></person-group><article-title>Recurrent ovarian cancer: when and how to treat</article-title><source>Curr Oncol Rep</source><year>2011</year><volume>13</volume><fpage>459</fpage><lpage>71</lpage><pub-id pub-id-type="doi">10.1007/s11912-011-0199-3</pub-id><pub-id pub-id-type="pmid">22045509</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hilpert</surname><given-names>F</given-names></name><name><surname>Wimberger</surname><given-names>P</given-names></name><name><surname>du Bois</surname><given-names>A</given-names></name><name><surname>Pfisterer</surname><given-names>J</given-names></name><name><surname>Harter</surname><given-names>P</given-names></name></person-group><article-title>Treatment of elderly ovarian cancer patients in the context of controlled clinical trials: a joint analysis of the AGO Germany experience</article-title><source>Onkologie</source><year>2012</year><volume>35</volume><fpage>76</fpage><lpage>81</lpage><pub-id pub-id-type="doi">10.1159/000336829</pub-id><pub-id pub-id-type="pmid">22414969</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Colombo</surname><given-names>N</given-names></name><etal/></person-group><article-title>Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up</article-title><source>Ann Oncol</source><year>2010</year><volume>21</volume><issue>Suppl 5</issue><fpage>v23</fpage><lpage>30</lpage><pub-id pub-id-type="doi">10.1093/annonc/mdq244</pub-id><pub-id pub-id-type="pmid">20555088</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lambrou</surname><given-names>NC</given-names></name><name><surname>Bristow</surname><given-names>RE</given-names></name></person-group><article-title>Ovarian cancer in elderly women</article-title><source>Oncology (Huntingt)</source><year>2003</year><volume>17</volume><fpage>1075</fpage><lpage>81</lpage><pub-id pub-id-type="pmid">12966676</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mahner</surname><given-names>S</given-names></name><etal/></person-group><article-title>A prospective multicenter study of treosulfan in elderly patients with recurrent ovarian cancer: results of a planned safety analysis</article-title><source>J Cancer Res Clin Oncol</source><year>2012</year><volume>138</volume><fpage>1413</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1007/s00432-012-1221-3</pub-id><pub-id pub-id-type="pmid">22526159</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Petignat</surname><given-names>P</given-names></name><etal/></person-group><article-title>Poorer survival of elderly patients with ovarian cancer: a population-based study</article-title><source>Surg Oncol</source><year>2004</year><volume>13</volume><fpage>181</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1016/j.suronc.2004.08.010</pub-id><pub-id pub-id-type="pmid">15615654</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Braicu</surname><given-names>EI</given-names></name><etal/></person-group><article-title>Primary versus secondary cytoreduction for epithelial ovarian cancer: a paired analysis of tumour pattern and surgical outcome</article-title><source>Eur J Cancer</source><year>2012</year><volume>48</volume><fpage>687</fpage><lpage>94</lpage><pub-id pub-id-type="doi">10.1016/j.ejca.2011.06.034</pub-id><pub-id pub-id-type="pmid">21757333</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kolb</surname><given-names>GF</given-names></name><name><surname>Weissbach</surname><given-names>L</given-names></name></person-group><article-title>Demographic change : changes in society and medicine and developmental trends in geriatrics</article-title><source>Urologe A</source><year>2015</year><volume>54</volume><fpage>1701</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1007/s00120-015-4004-z</pub-id><pub-id pub-id-type="pmid">26704273</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clegg</surname><given-names>A</given-names></name><name><surname>Young</surname><given-names>J</given-names></name><name><surname>Iliffe</surname><given-names>S</given-names></name><name><surname>Rikkert</surname><given-names>MO</given-names></name><name><surname>Rockwood</surname><given-names>K</given-names></name></person-group><article-title>Frailty in elderly people</article-title><source>Lancet</source><year>2013</year><volume>381</volume><fpage>752</fpage><lpage>62</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(12)62167-9</pub-id><pub-id pub-id-type="pmid">23395245</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nelson</surname><given-names>EC</given-names></name><etal/></person-group><article-title>Patient reported outcome measures in practice</article-title><source>BMJ</source><year>2015</year><volume>350</volume><fpage>g7818</fpage><pub-id pub-id-type="doi">10.1136/bmj.g7818</pub-id><pub-id pub-id-type="pmid">25670183</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Cock</surname><given-names>L</given-names></name><name><surname>Kieffer</surname><given-names>A</given-names></name><name><surname>Kurtz</surname><given-names>JE</given-names></name><name><surname>Joly</surname><given-names>F</given-names></name><name><surname>Weber</surname><given-names>B</given-names></name></person-group><article-title>[Expectations of patients with ovarian cancer. Results of the European investigation EXPRESSION III in French patients from GINECO group]</article-title><source>Bull Cancer</source><year>2015</year><volume>102</volume><fpage>217</fpage><lpage>25</lpage><pub-id pub-id-type="doi">10.1016/j.bulcan.2014.09.004</pub-id><pub-id pub-id-type="pmid">25749410</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oskay-Ozcelik</surname><given-names>G</given-names></name><etal/></person-group><article-title>Breast cancer patients&#x02019; expectations in respect of the physician-patient relationship and treatment management results of a survey of 617 patients</article-title><source>Ann Oncol</source><year>2007</year><volume>18</volume><fpage>479</fpage><lpage>84</lpage><pub-id pub-id-type="doi">10.1093/annonc/mdl456</pub-id><pub-id pub-id-type="pmid">17272832</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stuart</surname><given-names>GC</given-names></name><etal/></person-group><article-title>2010 Gynecologic Cancer InterGroup (GCIG) consensus statement on clinical trials in ovarian cancer: report from the Fourth Ovarian Cancer Consensus Conference</article-title><source>Int J Gynecol Cancer</source><year>2011</year><volume>21</volume><fpage>750</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.1097/IGC.0b013e31821b2568</pub-id><pub-id pub-id-type="pmid">21543936</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Petignat</surname><given-names>P</given-names></name><name><surname>Vlastos</surname><given-names>G</given-names></name></person-group><article-title>Why do ovarian cancer patients not consult a gynecologic oncologist?</article-title><source>Gynecol Oncol</source><year>2002</year><volume>87</volume><fpage>157</fpage><pub-id pub-id-type="doi">10.1006/gyno.2002.6782</pub-id><pub-id pub-id-type="pmid">12468361</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fotopoulou</surname><given-names>C</given-names></name><etal/></person-group><article-title>Clinical outcome of tertiary surgical cytoreduction in patients with recurrent epithelial ovarian cancer</article-title><source>Ann Surg Oncol</source><year>2011</year><volume>18</volume><fpage>49</fpage><lpage>57</lpage><pub-id pub-id-type="doi">10.1245/s10434-010-1245-3</pub-id><pub-id pub-id-type="pmid">20697821</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Singh</surname><given-names>JA</given-names></name><etal/></person-group><article-title>Preferred roles in treatment decision making among patients with cancer: a pooled analysis of studies using the Control Preferences Scale</article-title><source>Am J Manag Care</source><year>2010</year><volume>16</volume><fpage>688</fpage><lpage>96</lpage><pub-id pub-id-type="pmid">20873956</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pfeiffer</surname><given-names>P</given-names></name><etal/></person-group><article-title>Patient preference for oral or intravenous chemotherapy: a randomised cross-over trial comparing capecitabine and Nordic fluorouracil/leucovorin in patients with colorectal cancer</article-title><source>Eur J Cancer</source><year>2006</year><volume>42</volume><fpage>2738</fpage><lpage>43</lpage><pub-id pub-id-type="doi">10.1016/j.ejca.2006.06.027</pub-id><pub-id pub-id-type="pmid">17011184</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gropp</surname><given-names>M</given-names></name><name><surname>Meier</surname><given-names>W</given-names></name><name><surname>Hepp</surname><given-names>H</given-names></name></person-group><article-title>Treosulfan as an effective second-line therapy in ovarian cancer</article-title><source>Gynecol Oncol</source><year>1998</year><volume>71</volume><fpage>94</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1006/gyno.1998.5103</pub-id><pub-id pub-id-type="pmid">9784326</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Breitbach</surname><given-names>GP</given-names></name><etal/></person-group><article-title>Treosulfan in the treatment of advanced ovarian cancer: a randomised co-operative multicentre phase III-study</article-title><source>Anticancer Res</source><year>2002</year><volume>22</volume><fpage>2923</fpage><lpage>32</lpage><pub-id pub-id-type="pmid">12530019</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meier</surname><given-names>W</given-names></name><etal/></person-group><article-title>Topotecan versus treosulfan, an alkylating agent, in patients with epithelial ovarian cancer and relapse within 12 months following 1st-line platinum/paclitaxel chemotherapy. A prospectively randomized phase III trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR)</article-title><source>Gynecol Oncol</source><year>2009</year><volume>114</volume><fpage>199</fpage><lpage>205</lpage><pub-id pub-id-type="doi">10.1016/j.ygyno.2009.04.026</pub-id><pub-id pub-id-type="pmid">19446314</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hilger</surname><given-names>RA</given-names></name><etal/></person-group><article-title>Investigation of bioavailability and pharmacokinetics of treosulfan capsules in patients with relapsed ovarian cancer</article-title><source>Cancer Chemother Pharmacol</source><year>2000</year><volume>45</volume><fpage>483</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1007/s002800051023</pub-id><pub-id pub-id-type="pmid">10854136</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chekerov</surname><given-names>R</given-names></name><etal/></person-group><article-title>Treosulfan in the treatment of advanced ovarian cancer - results of a german multicenter non-interventional study</article-title><source>Anticancer Res</source><year>2015</year><volume>35</volume><fpage>6869</fpage><lpage>75</lpage><pub-id pub-id-type="pmid">26637909</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Senn</surname><given-names>S</given-names></name></person-group><article-title>Review of Fleiss, statistical methods for rates and proportions</article-title><source>Res Synth Methods</source><year>2011</year><volume>2</volume><fpage>221</fpage><lpage>2</lpage><pub-id pub-id-type="doi">10.1002/jrsm.50</pub-id><pub-id pub-id-type="pmid">26061787</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rustin</surname><given-names>GJ</given-names></name></person-group><article-title>Follow-up with CA125 after primary therapy of advanced ovarian cancer has major implications for treatment outcome and trial performances and should not be routinely performed</article-title><source>Ann Oncol</source><year>2011</year><volume>22</volume><issue>Suppl 8</issue><fpage>viii45</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1093/annonc/mdr471</pub-id><pub-id pub-id-type="pmid">22180399</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kurtz</surname><given-names>JE</given-names></name><etal/></person-group><article-title>Ovarian cancer in elderly patients: carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in late relapse: a Gynecologic Cancer Intergroup (GCIG) CALYPSO sub-study</article-title><source>Ann Oncol</source><year>2011</year><volume>22</volume><fpage>2417</fpage><lpage>23</lpage><pub-id pub-id-type="doi">10.1093/annonc/mdr001</pub-id><pub-id pub-id-type="pmid">21402619</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rowland</surname><given-names>JH</given-names></name><name><surname>Hewitt</surname><given-names>M</given-names></name><name><surname>Ganz</surname><given-names>PA</given-names></name></person-group><article-title>Cancer survivorship: a new challenge in delivering quality cancer care</article-title><source>J Clin Oncol</source><year>2006</year><volume>24</volume><fpage>5101</fpage><lpage>4</lpage><pub-id pub-id-type="doi">10.1200/JCO.2006.09.2700</pub-id><pub-id pub-id-type="pmid">17093270</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Economou</surname><given-names>D</given-names></name></person-group><article-title>Palliative care needs of cancer survivors</article-title><source>Semin Oncol Nurs</source><year>2014</year><volume>30</volume><fpage>262</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1016/j.soncn.2014.08.008</pub-id><pub-id pub-id-type="pmid">25361878</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barnholtz-Sloan</surname><given-names>JS</given-names></name><etal/></person-group><article-title>Ovarian cancer: changes in patterns at diagnosis and relative survival over the last three decades</article-title><source>Am J Obstet Gynecol</source><year>2003</year><volume>189</volume><fpage>1120</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1067/S0002-9378(03)00579-9</pub-id><pub-id pub-id-type="pmid">14586365</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brennan</surname><given-names>PF</given-names></name><name><surname>Strombom</surname><given-names>I</given-names></name></person-group><article-title>Improving health care by understanding patient preferences: the role of computer technology</article-title><source>J Am Med Inform Assoc</source><year>1998</year><volume>5</volume><fpage>257</fpage><lpage>62</lpage><pub-id pub-id-type="doi">10.1136/jamia.1998.0050257</pub-id><pub-id pub-id-type="pmid">9609495</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Say</surname><given-names>R</given-names></name><name><surname>Murtagh</surname><given-names>M</given-names></name><name><surname>Thomson</surname><given-names>R</given-names></name></person-group><article-title>Patients&#x02019; preference for involvement in medical decision making: a narrative review</article-title><source>Patient Educ Couns</source><year>2006</year><volume>60</volume><fpage>102</fpage><lpage>14</lpage><pub-id pub-id-type="doi">10.1016/j.pec.2005.02.003</pub-id><pub-id pub-id-type="pmid">16442453</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Degner</surname><given-names>LF</given-names></name><etal/></person-group><article-title>Information needs and decisional preferences in women with breast cancer</article-title><source>JAMA</source><year>1997</year><volume>277</volume><fpage>1485</fpage><lpage>92</lpage><pub-id pub-id-type="doi">10.1001/jama.1997.03540420081039</pub-id><pub-id pub-id-type="pmid">9145723</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hwang</surname><given-names>KH</given-names></name><name><surname>Cho</surname><given-names>OH</given-names></name><name><surname>Yoo</surname><given-names>YS</given-names></name></person-group><article-title>Symptom clusters of ovarian cancer patients undergoing chemotherapy, and their emotional status and quality of life</article-title><source>Eur J Oncol Nurs</source><year>2016</year><volume>21</volume><fpage>215</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.1016/j.ejon.2015.10.007</pub-id><pub-id pub-id-type="pmid">26645947</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mikhail</surname><given-names>SE</given-names></name><name><surname>Sun</surname><given-names>JF</given-names></name><name><surname>Marshall</surname><given-names>JL</given-names></name></person-group><article-title>Safety of capecitabine: a review</article-title><source>Expert Opin Drug Saf</source><year>2010</year><volume>9</volume><fpage>831</fpage><lpage>41</lpage><pub-id pub-id-type="doi">10.1517/14740338.2010.511610</pub-id><pub-id pub-id-type="pmid">20722491</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Woopen</surname><given-names>H</given-names></name><etal/></person-group><article-title>The influence of comorbidity and comedication on grade III/IV toxicity and prior discontinuation of chemotherapy in recurrent ovarian cancer patients: An individual participant data meta-analysis of the North-Eastern German Society of Gynecological Oncology (NOGGO)</article-title><source>Gynecol Oncol</source><year>2015</year><volume>138</volume><fpage>735</fpage><lpage>40</lpage><pub-id pub-id-type="doi">10.1016/j.ygyno.2015.07.007</pub-id><pub-id pub-id-type="pmid">26185017</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><mixed-citation publication-type="other">Donovan KA, et al. Recommended patient-reported core set of symptoms and quality-of-life domains to measure in ovarian cancer treatment trials. J Natl Cancer Inst. 2014;106(7):1&#x02013;4.</mixed-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>King</surname><given-names>MT</given-names></name><etal/></person-group><article-title>Development of the measure of ovarian symptoms and treatment concerns: aiming for optimal measurement of patient-reported symptom benefit with chemotherapy for symptomatic ovarian cancer</article-title><source>Int J Gynecol Cancer</source><year>2014</year><volume>24</volume><fpage>865</fpage><lpage>73</lpage><pub-id pub-id-type="doi">10.1097/IGC.0000000000000167</pub-id><pub-id pub-id-type="pmid">24844220</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tew</surname><given-names>WP</given-names></name><name><surname>Fleming</surname><given-names>GF</given-names></name></person-group><article-title>Treatment of ovarian cancer in the older woman</article-title><source>Gynecol Oncol</source><year>2015</year><volume>136</volume><fpage>136</fpage><lpage>42</lpage><pub-id pub-id-type="doi">10.1016/j.ygyno.2014.10.028</pub-id><pub-id pub-id-type="pmid">25448455</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sehouli</surname><given-names>J</given-names></name><etal/></person-group><article-title>Nonplatinum topotecan combinations versus topotecan alone for recurrent ovarian cancer: results of a phase III study of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group</article-title><source>J Clin Oncol</source><year>2008</year><volume>26</volume><fpage>3176</fpage><lpage>82</lpage><pub-id pub-id-type="doi">10.1200/JCO.2007.15.1258</pub-id><pub-id pub-id-type="pmid">18591555</pub-id></element-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Edwards</surname><given-names>SJ</given-names></name><name><surname>Barton</surname><given-names>S</given-names></name><name><surname>Thurgar</surname><given-names>E</given-names></name><name><surname>Trevor</surname><given-names>N</given-names></name></person-group><article-title>Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced recurrent or refractory ovarian cancer: a systematic review and economic evaluation</article-title><source>Health Technol Assess</source><year>2015</year><volume>19</volume><fpage>1</fpage><lpage>480</lpage></element-citation></ref></ref-list></back></article>